• Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=16630136).
  
• Mutation; HGNC; 950; BAP1; Simple; p.Tyr724Ter (c.2172delC); Zygosity=Unspecified (PubMed=26011428).
  
• Mutation; HGNC; 20796; RASSF6; Simple; p.Arg155fs (c.464_465insA); Zygosity=Unspecified (PubMed=25902174).
  

PubMed=16630136; DOI=10.1111/j.1349-7006.2006.00184.x; PMCID=PMC11158456
Usami N., Fukui T., Kondo M., Taniguchi T., Yokoyama T., Mori S., Yokoi K., Horio Y., Shimokata K., Sekido Y., Hida T.
Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients.
Cancer Sci. 97:387-394(2006)

PubMed=17270034; DOI=10.1111/j.1349-7006.2006.00386.x; PMCID=PMC11158069
Taniguchi T., Karnan S., Fukui T., Yokoyama T., Tagawa H., Yokoi K., Ueda Y., Mitsudomi T., Horio Y., Hida T., Yatabe Y., Seto M., Sekido Y.
Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32.
Cancer Sci. 98:438-446(2007)

PubMed=21245096; DOI=10.1158/0008-5472.CAN-10-2164
Murakami H., Mizuno T., Taniguchi T., Fujii M., Ishiguro F., Fukui T., Akatsuka S., Horio Y., Hida T., Kondo Y., Toyokuni S., Osada H., Sekido Y.
LATS2 is a tumor suppressor gene of malignant mesothelioma.
Cancer Res. 71:873-883(2011)

PubMed=25902174; DOI=10.1097/JTO.0000000000000493
Miyanaga A., Masuda M., Tsuta K., Kawasaki K., Nakamura Y., Sakuma T., Asamura H., Gemma A., Yamada T.
Hippo pathway gene mutations in malignant mesothelioma: revealed by RNA and targeted exon sequencing.
J. Thorac. Oncol. 10:844-851(2015)

PubMed=26011428; DOI=10.1111/cas.12698; PMCID=PMC4556387
Hakiri S., Osada H., Ishiguro F., Murakami H., Murakami-Tonami Y., Yokoi K., Sekido Y.
Functional differences between wild-type and mutant-type BRCA1-associated protein 1 tumor suppressor against malignant mesothelioma cells.
Cancer Sci. 106:990-999(2015)

PubMed=28553954; DOI=10.1038/onc.2017.147
Kato T., Sato T., Yokoi K., Sekido Y.
E-cadherin expression is correlated with focal adhesion kinase inhibitor resistance in merlin-negative malignant mesothelioma cells.
Oncogene 36:5522-5531(2017)